52 results on '"Videla, Sebastián"'
Search Results
2. Long-term follow-up of total hip arthroplasty using polyethylene-ceramic composite (sandwich) liner.
- Author
-
Rodríguez-Pérez, Daniel, Carnaval, Thiago, Rodríguez, Marcos-del-Carmen, Coscujuela-Maña, Antonio, Agulló, José-Luis, and Videla, Sebastián
- Subjects
RISK assessment ,TOTAL hip replacement ,COMPLICATIONS of prosthesis ,SCIENTIFIC observation ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,TERTIARY care ,SURGICAL complications ,BONE fractures ,LONGITUDINAL method ,KAPLAN-Meier estimator ,ARTIFICIAL joints ,REOPERATION ,ARTHRITIS ,POLYETHYLENE ,CONFIDENCE intervals ,SURVIVAL analysis (Biometry) ,HIP osteoarthritis ,OSTEONECROSIS ,DISEASE risk factors - Abstract
Introduction: Ceramic-on-ceramic bearings have been widely used since their introduction in the 1970s. First-generation ceramics have very high fracture (breakage) rates. To overcome this, in the 1990s, modular cotyloid insert designs were developed, consisting of a ceramic and polyethylene composite (sandwich-type) liner; however, high implant fracture rates were observed in the medium term. We aimed to estimate the cumulative incidences of revision surgery (implant failure) and implant failure due to fractures, survival rates (time-to-revision surgery and time-to-fracture), and the long-term clinical and radiological outcomes in our series. Methods: This was an observational, longitudinal, ambispective, single-centre study based on patients who underwent primary total hip arthroplasty (THA) using a sandwich-type liner (Cerasul), only available in our tertiary hospital between January 1999 and December 2002. Cumulative incidences were estimated and the 95% confidence interval (95% CI) was calculated. The Kaplan-Meier method was used to assess the time-to-revision surgery and time-to-fracture. Results: 54 patients (49 men) were included, accounting for 59 sandwich-type linear implants. The mean (range) age was 47.4 (22–57) years. The primary THA indications were osteoarthritis (28 patients), osteonecrosis (14), childhood pathology sequelae (11), and inflammatory arthritis (6). The cumulative incidence of revision surgery by implants was 8.5% (5/59, 95% CI, 3.5–19.2%), 9.3% by patients (5/54, 95% CI, 4.0–19.9%), and 5.1% by implant fractures (3/59, 95%CI, 1.7–13.9%). The median (Interquartile Range, IQR) time-to-revision surgery was 158 (72.5–161) months, and the time to fracture was 182 (138–215) months. All primary THAs had good clinical and long-term survival outcomes. All implants had signs of solid fixation. Conclusions: After a 20-year follow-up period, the polyethylene-ceramic sandwich-type liner showed a long survival rate and low cumulative incidence of implant fracture; however, implant fractures remain the main complication. Orthopaedic surgeons should be aware that some patients still have this type of prosthesis and must be capable of responding quickly if a fracture occurs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Radiculopathy with motor deficit: a cross-sectional study of the impact of the surgeon's experience on the indication and timing of surgical treatment.
- Author
-
Garreta-Catala, Iago, Suarez-Perez, Moises, Gonzalez-Cañas, Lluis, Covaro, Augusto, Videla, Sebastián, Nolla, Joan M., and Agullo-Ferre, Jose-Luis
- Subjects
WORK experience (Employment) ,CONSERVATIVE treatment ,RESEARCH ,CONFIDENCE intervals ,TIME ,CROSS-sectional method ,MOVEMENT disorders ,MAGNETIC resonance imaging ,RADICULOPATHY ,SURVEYS ,CLINICAL competence ,QUESTIONNAIRES ,DECISION making in clinical medicine ,LITERATURE reviews ,DISEASE complications - Abstract
Purpose: The optimal management of patients with compressive radiculopathy with motor deficit (CRMD) is controversial. Our goal was to provide evidence on the impact of the spine surgeons' experience on surgical planning and timing. Methods: Spine surgeons were invited to participate in a 5-item online survey. A literature review was carried out. Results: Of the 94 spine surgeons who responded to the survey, 70% would operate early on a patient with acute CRMD, but only 48% would do so if the radicular pain had resolved. Surgeons with more than 15 years of experience chose more conservative options. Twenty published studies were selected in the literature review. Conclusion: The optimal management of patients with compressive radiculopathy associated with a non-progressive motor loss remains unknown. The results of our survey show that surgeons with extensive surgical experience take a more conservative and cautious approach. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Feasibility of a multidisciplinary group videoconferencing approach for chronic low back pain: a randomized, open-label, controlled, pilot clinical trial (EN-FORMA).
- Author
-
Garreta-Catala, Iago, Planas-Balagué, Rosa, Abouzari, Reza, Carnaval, Thiago, Nolla, Joan M., Videla, Sebastián, Agulló-Ferré, José-Luis, Calvis-Garcia, Paula, Carmezim, João, Company-Llimona, Anna, Fernandez-Mariscal, Esmeralda, Fernandez-Solana, Coral, Figuerola-Batista, Montserrat, Gerique-Fornas, Neus, Grifell-Martín, Encarna, Gutierrez-Jimenez, Nuria, Mariano-Martin, Nuria, Mas-Garriga, Xavier, Otero-Gonzalez, Aurema, and Soler-Soto, Sandra
- Subjects
CHRONIC pain ,VIDEOCONFERENCING ,SPARE parts ,LUMBAR pain ,CLINICAL trials - Abstract
Background: Low back pain is a common condition that becomes even more prevalent with aging. A non-pharmacological multidisciplinary approach for chronic non-specific low back pain (CNSLBP) has been recommended, but integrating different healthcare professionals is challenging. A multidisciplinary group videoconferencing approach (MGVA) can be helpful. Our aim was to provide evidence on MGVA's feasibility in managing CNSLBP and its impact on clinical practice. Methods: We conducted an open-label, randomized, controlled, parallel-group pilot clinical trial with CNSLBP patients irresponsive to conservative treatment. Patients between 18 and 67 years of age were randomly assigned (1:1) to either Standard-of-Care + MGVA (experimental group) or Standard-of-Care alone (control group). MGVA consisted of integrated sessions for physical rehabilitation/physiotherapy, psychology, and social work treatments. The control group received standard clinical practice treatment. The feasibility was assessed by the number of study procedures completed to at least 80% as planned. The impact on clinical practice was evaluated by the number of patients who changed their status from "candidate" to "non-candidate" to low back surgery as the treatment of choice for CNSLBP. The SF–36, Oswestry Disability Index, and TMMS–24 questionnaires were used. We performed a whole population-based descriptive analysis. Results: We included 20 patients, but only 18 were randomized (2 withdrew consent before randomization). The mean (SD) age was 53.1 (5.9) years, and mostly women (13/18); 7 were actively employed. In the experimental group, 6/9 (67%, 95%CI:35–88%) patients attended at least 80% of the scheduled procedures, while in the control group, 8/9 (89%, 95%CI:57–98%) did. Additionally, 1 out of 4 (25%) patients in the experimental group changed their status from "candidate" for low back surgery to "non-candidate". None of the 2 patients in the control group did so. We found differences between groups in the SF-36 mental health component (p-value:0.061), Oswestry Disability Index (p-value:0.032), and TMMS-24 Repair component (p-value:0.014) at the end of the trial favoring MGVA. Conclusions: The multidisciplinary group videoconferencing approach to managing chronic non-specific low back pain was feasible, suggesting overall beneficial effects on patients' health and could play a role in changing a patient's status from "candidate" to "non-candidate" for surgery. Trial registration: NCT05093543 (ClinicalTrials.gov), first registered in 26/10/2021. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Indocyanine green angiography-guided thyroidectomy versus conventional thyroidectomy for preserving parathyroid function: study protocol for a randomized single-blind controlled trial.
- Author
-
Moreno-Llorente, Pablo, García-González, Guillermo, Pascua-Solé, Mireia, García-Barrasa, Arantxa, Videla, Sebastián, and Luis Muñoz-de-Nova, José
- Subjects
THYROIDECTOMY ,INDOCYANINE green ,RANDOMIZED controlled trials ,PARATHYROID glands ,RESEARCH protocols - Abstract
Introduction: Angiography with indocyanine green (ICG) fluorescence performed before thyroidectomy would allow identification of the vascularization of parathyroid glands, maximizing efforts for preserving functioning glands intraoperatively. The rationale of the study was based on the hypothesis that showing the vascular pattern of the parathyroid glands by means of ICG angiography before performing the thyroidectomy could prevent permanent hypoparathyroidism. Methods and analysis: We propose a randomized single-blind controlled and multicenter clinical trial to assess the efficacy and safety of ICG angiographyguided thyroidectomy to identify the vascular pattern of the parathyroid glands versus conventional thyroidectomy in patients scheduled for elective total thyroidectomy. Patients will be randomized 1:1 to ICG angiography-guided thyroidectomy (experimental group) or conventional thyroidectomy (control group). Patients in the experimental group will undergo ICG angiography before thyroidectomy to identify the feeding vessels of the parathyroid glands and then, post-thyroidectomy ICG angiography to predict immediate parathyroid gland function by scoring the degree of fluorescence of the glands. Patients in the control group will undergo post-thyroidectomy ICG angiography only. The primary outcome measure will be the rate of patients with permanent hypoparathyroidism. Secondary outcome measures will be rate of postoperative hypoparathyroidism, the percentage of well vascularized parathyroid glands remaining in situ, the levels of iPTH and serum calcium after surgery and the influence of the type of vascular pattern of the parathyroid glands over these outcomes, as well as the safety profile of ICG angiography. Discussion: The results will contribute to adopt a new surgical strategy based on intraoperative ICG angiography before performing total thyroidectomy, according to which the rate of permanent hypoparathyroidism could be substantially reduced. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.
- Author
-
Malchair, Pierre, Giol, Jordi, García, Vanesa, Rodríguez, Orlando, Ruibal, José Carlos, Zarauza, Alvaro, Llopis, Ferrán, Matellán, Leire, Bernal, Tania, Solís, Beatriz, Otero, Aurema, Carnaval, Thiago, Jofre, Hector, Jacob, Javier, Solanich, Xavier, Antolí, Arnau, Rocamora, Gemma, and Videla, Sebastián
- Subjects
PNEUMONIA-related mortality ,PNEUMONIA ,DRUG efficacy ,PATIENT aftercare ,COVID-19 ,CONFIDENCE intervals ,CELL receptors ,RANDOMIZED controlled trials ,COMPARATIVE studies ,VASODILATORS ,DESCRIPTIVE statistics ,RESEARCH funding ,HYPOXEMIA ,EVALUATION - Abstract
Background We aimed to evaluate icatibant, a competitive antagonist of the bradykinin B2 receptors, for the treatment of inpatients with coronavirus disease 2019 (COVID-19) pneumonia admitted in the early hypoxemic stage. Methods The randomized, open-label clinical trial of icatibant for COVID-19 pneumonia (ICAT·COVID, registered as NCT04978051 at ClinicalTrials.gov) was conducted in Barcelona. Inpatients requiring supplemental but not high-flow oxygen or mechanical ventilation were allocated (1:1) to treatment with either three 30-mg icatibant doses/d for 3 consecutive days plus standard care or standard care alone, and followed for up to 28 days after initial discharge. The primary and key secondary outcomes were clinical response on study day 10/discharge and clinical efficacy at 28 days from initial discharge, respectively. Results Clinical response occurred in 27 of 37 patients (73.0%) in the icatibant group and 20 of 36 patients (55.6%) in the control group (rate difference, 17.42; 95% confidence interval [CI], −4.22 to 39.06; P =.115). Clinical efficacy ensued in 37 patients (100.0%) in the icatibant group and 30 patients (83.3%) in the control group (rate difference, 16.67; 95% CI, 4.49-28.84; P =.011). No patient died in the icatibant group, compared with 6 patients (16.7%) in the control group (P =.011). All patients but 1 had adverse events, which were evenly distributed between study arms. No patient withdrew because of adverse events. Conclusions Adding icatibant to standard care was safe and improved both COVID-19 pneumonia and mortality in this proof-of-concept study. A larger, phase 3 trial is warranted to establish the clinical value of this treatment. Clinical Trials Registration NCT04978051. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid Function.
- Author
-
Moreno-Llorente, Pablo, García-Barrasa, Arantxa, Pascua-Solé, Mireia, Videla, Sebastián, Otero, Aurema, and Muñoz-de Nova, José Luis
- Subjects
THYROIDECTOMY ,PARATHYROID glands ,INDOCYANINE green ,DIETARY supplements ,HYPOCALCEMIA ,VITAMIN D - Abstract
Introduction: Hypoparathyroidism is the most frequent complication after total thyroidectomy and, when permanent, it becomes a severe chronic disease. We assessed the usefulness of indocyanine green (ICG) angiography-guided thyroidectomy to reduce the postoperative hypocalcemia. Methods: Prospective study with two consecutive cohorts of patients who underwent total thyroidectomy: historical control group (CG) and angiography-guided thyroidectomy group (AG). In all patients, ICG-angiography was performed at the end of the surgery to predict immediate parathyroid gland (PG) function. In the AG, ICG-angiography was also done after PG identification to show their vascular supply. We compared the rate of postoperative hypocalcemia (calcium supplementation needed due to hypocalcemia symptoms or calcium levels < 1.8 mmol/L on the first postoperative day) and permanent hypocalcemia (need of calcium ± vitamin D supplementation 12 months after thyroidectomy). Results: We included 120 consecutive patients (84 CG; 36 AG). Thyroid cancer was the most common diagnostic (63.1% CG–69.4% AG; p = 0.646) and central neck dissection was also frequent (54.8% CG–64.3% AG; p = 0.468). The AG developed a lower rate of postoperative (26.2–5.6%; p = 0.011) and permanent hypocalcemia (11.9–0%; p = 0.032). The OR for permanent hypocalcemia was 0.673 (95% CI 0.591–0.766). A significant higher rate of well vascularized PG at the end of the surgery (score 2) in the AG (39.2–52.9%; p = 0.018) was also seen. Conclusion: ICG angiography-guided thyroidectomy is a useful tool to identify PG vascularization, allowing a better PG preservation and a significant decrease in hypocalcemia rates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: A phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial.
- Author
-
Viscusi, Eugene R., de Leon‐Casasola, Oscar, Cebrecos, Jesús, Jacobs, Adam, Morte, Adelaida, Ortiz, Esther, Sust, Mariano, Vaqué, Anna, Gottlieb, Ira, Daniels, Stephen, Gimbel, Joseph S., Muse, Derek, Winkle, Peter, Kuss, Michael E., Videla, Sebastián, Gascón, Neus, and Plata‐Salamán, Carlos
- Subjects
CYCLOOXYGENASE 2 ,DRUG efficacy ,RESEARCH ,COMBINATION drug therapy ,PAIN measurement ,CONFIDENCE intervals ,ANALGESIA ,NONSTEROIDAL anti-inflammatory agents ,TRAMADOL ,OSTEOTOMY ,ORAL drug administration ,BUNION surgery ,SEVERITY of illness index ,RANDOMIZED controlled trials ,RESEARCH funding ,BLIND experiment ,DESCRIPTIVE statistics ,STATISTICAL sampling ,POSTOPERATIVE pain ,THERAPEUTICS - Abstract
Background: Celecoxib‐tramadol co‐crystal (CTC) is a first‐in‐class analgesic co‐crystal of celecoxib and racemic tramadol with an improved pharmacologic profile, conferred by the co‐crystal structure, compared with its active constituents administered alone/concomitantly. Aim: We evaluated CTC in moderate‐to‐severe acute postoperative pain. Materials and Methods: This randomized, double‐blind, factorial, active‐ and placebo‐controlled phase 3 trial (NCT03108482) was conducted at 6 US clinical research centers. Adults with moderate‐to‐severe acute pain following bunionectomy with osteotomy were randomized to oral CTC (200 mg [112 mg celecoxib/88 mg rac‐tramadol hydrochloride] every 12 h), tramadol (50 mg every 6 h), celecoxib (100 mg every 12 h), or placebo for 48 h. Patients, investigators, and personnel were blinded to assignment. The primary endpoint was the 0–48 h sum of pain intensity differences (SPID0–48) in all randomized patients. Pain intensity was assessed on a 0–10 numerical rating scale (NRS). Safety was analyzed in patients who received study medication. Funded by ESTEVE Pharmaceuticals. Results: In 2017 (March to November), 1323 patients were screened and 637 randomized to CTC (n = 184), tramadol (n = 183), celecoxib (n = 181), or placebo (n = 89). Mean baseline NRS was 6.7 in all active groups. CTC had a significantly greater effect on SPID0–48 (least‐squares mean: −139.1 [95% confidence interval: −151.8, −126.5]) than tramadol (−109.1 [−121.7, −96.4]; p < 0.001), celecoxib (−103.7 [−116.4, −91.0]; p < 0.001), or placebo (−74.6 [−92.5, −56.6]; p < 0.001). Total treatment‐emergent adverse events (TEAEs) were 358 for CTC and 394 for tramadol. Drug‐related TEAEs occurred in 37.7% patients in the CTC group, compared with 48.6% in the tramadol group. There were no serious TEAEs/deaths. Conclusion: CTC provided greater analgesia than comparable daily doses of tramadol and celecoxib, with similar tolerability to tramadol. CTC is approved in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Characteristics and Outcomes by Ceiling of Care of Subjects Hospitalized with COVID-19 During Four Waves of the Pandemic in a Metropolitan Area: A Multicenter Cohort Study.
- Author
-
Pallarès, Natàlia, Tebé, Cristian, Abelenda-Alonso, Gabriela, Rombauts, Alexander, Oriol, Isabel, Simonetti, Antonella F., Rodríguez-Molinero, Alejandro, Izquierdo, Elisenda, Díaz-Brito, Vicens, Molist, Gemma, Gómez Melis, Guadalupe, Carratalà, Jordi, Videla, Sebastián, the MetroSud and Divine study groups, Gudiol, Carlota, Aranda-Lobo, Judit, Arroyo, Marta, Pérez-López, Carlos, Sanmartí, Montserrat, and Moreno, Encarna
- Subjects
COVID-19 pandemic ,HOSPITAL medical staff ,METROPOLITAN areas ,COVID-19 ,COHORT analysis - Abstract
Introduction: The profiles of patients with COVID-19 have been widely studied, but little is known about differences in baseline characteristics and in outcomes between subjects with a ceiling of care assigned at hospital admission and subjects without a ceiling of care. The aim of this study is to compare, by ceiling of care, clinical features and outcomes of hospitalized subjects during four waves of COVID-19 in a metropolitan area in Catalonia. Methods: Observational study conducted during the first (March–April 2020), second (October–November 2020), third (January–February 2021), and fourth wave (July–August 2021) of COVID-19 in five centers of Catalonia. All subjects were adults (> 18 years old) hospitalized with a proven SARS-CoV-2 infection and with therapeutic ceiling of care assessed by the attending physician at hospital admission. Results: A total of 5813 subjects were analyzed. Subjects with a ceiling of care were mainly older (difference in median age of 20 years), with more comorbidities (Charlson index 3 points higher) and with fewer clinical signs at baseline than patients without a ceiling of care. Some features of their clinical profiles changed among waves. There were differences in treatments received during hospital admission across waves, but not between subjects with and without a ceiling of care. Subjects with a ceiling of care had a death incidence more than four times the death incidence of subjects a without a ceiling of care (risk ratio (RR) ranging from 3.5 in the first wave to almost 6 in the third and fourth). Incidence of severe pneumonia and complications for subjects with a ceiling of care was around 1.5 times the incidence in subjects without a ceiling of care. Discussion: Analysis of hospitalized subjects with SARS-CoV-2 infection should be stratified according to therapeutic ceiling of care to avoid bias and outcome misestimation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease.
- Author
-
Benejam, Bessy, Aranha, Mateus Rozalem, Videla, Laura, Padilla, Concepción, Valldeneu, Silvia, Fernández, Susana, Altuna, Miren, Carmona-Iragui, Maria, Barroeta, Isabel, Iulita, Maria Florencia, Montal, Víctor, Pegueroles, Jordi, Bejanin, Alexandre, Giménez, Sandra, González-Ortiz, Sofía, Videla, Sebastián, Bartrés-Faz, David, Alcolea, Daniel, Blesa, Rafael, and Lleó, Alberto
- Subjects
ALZHEIMER'S disease ,EPISODIC memory ,DOWN syndrome ,RECOLLECTION (Psychology) ,CEREBRAL atrophy ,CINGULATE cortex - Abstract
Background: Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease. Methods: Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability. Results: Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects. Conclusions: Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.
- Author
-
Sirera, Guillem, Videla, Sebastián, Saludes, Verónica, Castellà, Eva, Sanz, Carolina, Ariza, Aurelio, Clotet, Bonaventura, and Martró, Elisa
- Subjects
LUNG cancer ,PAPILLOMAVIRUSES ,CANCER patients ,MESSENGER RNA ,SQUAMOUS cell carcinoma ,GENE expression - Abstract
HIV-infected individuals could be at a greater risk for developing lung cancer than the general population due to the higher prevalence in the former of human papillomavirus (HPV) in the oral cavity and higher smoking rates. Our aim was to assess HPV prevalence and E6 viral oncogene transcription in lung cancer samples from HIV-infected individuals. This was a single-center, retrospective study of a cohort of HIV-1-infected patients diagnosed with and treated for lung cancer. Pathological lung samples archived as smears or formalin-fixed paraffin-embedded blocks were subjected to HPV genotyping, detection of human p16 protein and assessment for HPV E6 mRNA expression. Lung cancer samples from 41 patients were studied, including squamous cell carcinoma (32%), adenocarcinoma (34%), non-small cell cancer (27%), and small cell cancer (7%). HPV DNA was detected in 23 out of 41 (56%, 95% CI 41–70%) of samples and high-risk (HR)-HPV types were detected in 16 out of 41 (39%, 95% CI 26–54%), HPV-16 being the most prevalent [13/16 (81.3%, 95% CI 57.0–93%]. In samples with sufficient material left: expression of p16 was detected in 3 out of 10 (30%) of HR-HPV DNA-positive tumors and in 3 out of 7 (43%) of the negative ones; and E6 mRNA was detected in 2 out of 10 (20%) of HPV-16-positive samples (squamous lung cancers). These two patients had a background of a previous HPV-related neoplasia and smoking. HR-HPV DNA detection was prevalent in lung cancers in HIV-infected patients. However, viral oncogene expression was limited to patients with previous HPV-related cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)
- Author
-
Malchair, Pierre, Otero, Aurema, Giol, Jordi, Solanich, Xavier, Carnaval, Thiago, Fernández-Nistal, Alonso, Sánchez-Gabriel, Ana, Montoto, Carmen, Lleonart, Ramon, and Videla, Sebastián
- Subjects
POSITIVE pressure ventilation ,ARTIFICIAL respiration ,COVID-19 ,SARS-CoV-2 ,PATIENT safety ,ADULT respiratory distress syndrome ,BRADYKININ receptors ,THROMBIN receptors - Abstract
Background: COVID-19 has quickly become a global pandemic with a substantial number of deaths and is a considerable burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection-related symptoms, some patients evolve to a second phase, with an impaired inflammatory response (cytokine storm) that may lead to acute respiratory distress syndrome and death. This is thought to be caused by increased bradykinin synthesis. Methods: ICAT-COVID is a multicenter, randomized, open-label, proof-of-concept phase II clinical trial assessing the clinical efficacy and safety of adding icatibant to the standard of care in patients hospitalized with COVID-19 without invasive mechanical ventilation. Patients hospitalized with a confirmed COVID-19 pneumonia diagnosis (RTPCR or antigen test = 10 days prior to randomization, and radiographic evidence of pulmonary infiltrates), rated "4" or "5" on the WHO's clinical status scale, are eligible. Patients will be randomized on a 1:1 ratio to either standard of care-plus-icatibant (experimental group) or to standard of care alone (control group). The experimental group will receive 30 mg of icatibant subcutaneously 3 times a day for 3 days (for a total of 9 doses). The expected sample size is 120 patients (60 per group) from 2 sites in Spain. Primary outcomes are the efficacy and safety of Icatibant. The main efficacy outcome is the number of patients reaching grades "2" or "1" on the WHO scale within 10 days of starting treatment. Secondary outcomes include "long-term efficacy": number of patients discharged who do not present COVID-19-related relapse or comorbidity up until 28 days after discharge, and mortality. Discussion: Icatibant, a bradykinin type 2 receptor antagonist with proven effectiveness and safety against hereditary angioedema attacks, may be beneficial for COVID-19 patients by inhibiting bradykinin's action on endothelial cells and by inhibiting the SARS-CoV-2 M protease. Our working hypothesis is that treatment with standard of care-plus-icatibant is effective and safe to treat patients infected with SARS-CoV-2 admitted to hospital for pneumonia without invasive mechanical ventilation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement.
- Author
-
González Osuna, Aránzazu, Rojas, Luisa Fernanda, Lamas, Claudia, Aguilera Roig, Xavier, Pla-Junca, Francesc, Videla, Sebastián, Martínez-Zapata, Mª José, Valle, Marta, FARMATX study group, Font Gual, Adriá, Ramirez, Eduard, Cánovas Martínez, Esther, Fernández Nuñez, José Antonio, González Rodriguez, José Carlos, Jordán Sales, Marcos, Rodríguez Prieto, Mireia, and Baños Lapuente, Victoria
- Subjects
TOTAL knee replacement ,INTRAVENOUS therapy ,TRANEXAMIC acid ,KNEE ,PHARMACOKINETICS ,BODY mass index ,BIOAVAILABILITY ,WOUND healing - Abstract
Background: Tranexamic acid (TXA), an antifibrinolytic drug, is usually administered intravenously; however, intra-articular administration has recently been proven to be as effective as intravenous administration. Limited information regarding the pharmacokinetics (PK) of TXA after intra-articular administration has been reported. Aims: The aim of this study was to develop a population PK model of TXA administered as a single intra-articular dose and as two intravenous doses, and to study the sources of interindividual variability (IIV) in the PK processes of TXA. The developed model was used to simulate PK profiles of TXA at different dosage regimens and in patients with renal impairment. Methods: Patients who underwent primary unilateral total knee replacement (TKR) received 1 g/10 mL (concentration of 100 mg/mL) of TXA applied directly to the surgical field before wound closure, or 2 g (two doses of 1 g) of intravenous TXA. A population PK model was developed using a nonlinear mixed-effects approach and sources of IIV, such as sex, age, body weight, height, body mass index (BMI), preoperative haemoglobin, preoperative haematocrit, and creatinine clearance. Results: Twenty-four patients were included, 12 in each group. Twenty patients were female, mean age (standard deviation) was 73.7 years (5.6). The disposition of TXA was best described as a two-compartment model with clearance dependent on creatinine clearance. Bootstrap results indicated that the model was stable and robust. The estimated bioavailability for intra-articular administration was 81%. Simulations indicated that 100% of patients would have plasma concentrations associated with partial fibrinolysis at 8 h post-administration with the dosages and routes of administration used in the present study. Intra-articular administration would produce complete inhibition of fibrinolysis in only 12% of patients compared with 72.5% with intravenous administration. No adverse events were reported. Conclusions: This population PK model demonstrated that a single dose of high-concentration, low-volume intra-articular TXA can achieve antifibrinolytic plasma concentrations of the drug for 8 h, providing both local and systemic effects in patients undergoing TKR. TXA administration to the surgical field could be an alternative to the intravenous; route for patients undergoing TKR; however, clinical studies are needed to assess the toxic local effects of TXA. Trial Registration : Spanish Clinical Studies Registry Number: 2017-004059-22. Date of registration: 12 April 2018. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Comparison of two sample collection devices for anal cytology in HIV‐positive men who have sex with men: Cytology brush and Dacron swab.
- Author
-
Silva‐Klug, Ana C., Saumoy, Maria, Baixeras, Nuria, Trenti, Loris, Catala, Isabel, Vidal, August, Torres, Montserrat, Alemany, Laia, Videla, Sebastián, De San Jose, Silvia, and Podzamczer, Daniel
- Subjects
HIV-positive men ,CIRCULATING tumor DNA ,MEN who have sex with men ,ANAL cancer ,CYTOLOGY ,RECEIVER operating characteristic curves - Abstract
Objective: HIV‐positive men who have sex with men (MSM) are a vulnerable group for anal cancer (AC), a cancer with a well‐described precursor lesion, which can be detected early in screening programs using anal liquid‐based cytology (aLBC). We aim to compare two aLBC sample collection devices: cytology brush (CB) and Dacron swab (DS). Methods: Retrospective analysis of two consecutive study periods, the first using CB and the second DS. Participants underwent an aLBC, a human papillomavirus (HPV) DNA test and a high‐resolution anoscopy (HRA), and a biopsy was performed for suspicious lesions. The sensitivity and specificity of aLBC, area under the receiver operating characteristic (ROC) curve (AUC), and concordance between cytology and HRA were assessed using Cohen's kappa coefficient. Results: A total of 239 participants were enrolled (CB group, 120; DS group, 119). aLBC was benign in 46% of samples, and high‐grade squamous intraepithelial lesion (HSIL) was detected in 11.7%. Prevalence of biopsy‐proven HSIL was 15.3%. No differences in cytological and histological results were observed between the groups. aLBC‐HRA concordance was weak for benign results (CB group, k = 0.309; DS group, k = 0.350) as well as for HSIL (k = 0.321 and 0.387, respectively). Sensitivity and specificity were 100% and 51.4%, respectively, in the CB group and 88% and 54.3% in the DS group (AUC = 0.711 and 0.759, respectively, P‐value =.514). Representation of the transformation zone (TZ) was adequate in 83.3% of samples in the CB group and 50.4% in the DS group (P‐value <.001). Conclusion: Our data suggest that both devices had similar accuracy to detect anal HSIL, although samples collected with CB are more likely to have an adequate TZ representation, the presence of which could be an indicator of sample quality. This article aims to compare two anal cytology sample collection devices for anal cancer screening in HIV‐positive men who have sex with men: cytology brush and Dacron swab. The results suggest that both devices have similar accuracy to detect anal HSIL, although samples collected with CB are more likely to have an adequate TZ representation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study.
- Author
-
Revollo, Boris, Videla, Sebastián, Llibre, Josep M, Paredes, Roger, Piñol, Marta, García-Cuyàs, Francesc, Ornelas, Arelly, Puig, Jordi, Parés, David, Corral, Javier, Clotet, Bonaventura, and Sirera, Guillem
- Subjects
ANUS ,CANCER invasiveness ,COMPARATIVE studies ,CONFIDENCE intervals ,CYTOLOGY ,HEALTH facilities ,HIV-positive persons ,LONGITUDINAL method ,MEDICAL records ,MEDICAL referrals ,PAPILLOMAVIRUSES ,PROBABILITY theory ,RISK assessment ,SQUAMOUS cell carcinoma ,DISEASE incidence ,RETROSPECTIVE studies ,ANAL tumors ,DESCRIPTIVE statistics ,EARLY detection of cancer ,ACQUISITION of data methodology ,DISEASE risk factors ,EVALUATION - Abstract
Background The efficacy of screening programs to prevent anal cancer in persons with human immunodeficiency virus 1 (HIV-1) is unclear. Methods To examine the impact of a screening program to detect anal cancer precursors on the incidence of cases of invasive anal squamous-cell carcinoma (IASCC) in persons with HIV-1, we performed a single-center, retrospective analysis of a prospective cohort of outpatients with HIV-1 attending a reference HIV unit from January 2005 onward. All participants were invited to participate in a continued structured screening program for anal cancer prevention. We estimated the incidence of IASCC and performed a comparative analysis between subjects enrolled in the screening program (screening group) and those who declined to participate (nonscreening group). To reduce any selection bias, a propensity score analysis was applied. Results We included 3111 persons with HIV-1 (1596 men-who-have-sex-with-men [MSM], 888 men-who-have-sex-with-women [MSW], 627 women; mean age, 41 years), with a median follow-up of 4.7 years (14 595 patient-years of follow-up); 1691 (54%) participated in the screening program. Ten patients were diagnosed with IASCC: 2 (MSM) in the screening group and 8 (4 MSM, 2 MSW, and 2 women) in the nonscreening group. The incidence rates of IASCC were 21.9 (95% confidence interval [CI], 2.7–70.3) and 107.0 (95% CI, 46.2–202.0) per 100 000 person-years, respectively. After a propensity score adjustment, the difference was significant in favor of the screening group (hazard ratio, 0.17; 95% CI,.03–.86). Conclusions The number of cases of IASCC was significantly lower in persons with HIV engaged in an anal cytology screening program. These results should be validated in a randomized clinical trial. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Evaluation of Potential Pain Biomarkers in Saliva and Pain Perception After Corneal Advanced Surface Ablation Surgery.
- Author
-
Sobas, Eva M, Vázquez, Amanda, Videla, Sebastián, Reinoso, Roberto, Fernández, Itziar, Garcia-Vazquez, Carmen, Maldonado, Miguel J, and Pastor, J Carlos
- Subjects
PAIN perception ,SALIVA analysis ,BIOMARKERS ,BIOLOGICAL tags ,SALIVA ,PAIN - Abstract
Purpose: To evaluate the evolution of a set of proposed pain biomarkers in the saliva of subjects following Advanced Surface Ablation (ASA), in order to determine their validity as objective pain measures. Methods: A multicenter, prospective, and descriptive study was carried out to assess the variations between biomarkers and perceived pain. The Inclusion criteria were healthy subjects who underwent a bilateral, alcohol-assisted surface ablation with epithelial removal (ASA). Pain intensity before and after surgery was assessed by Visual Analog Scale (VAS) and the Numeric Pain Rating Scale (NPRS). Cortisol, sAA, sIgA, testosterone, and sTNFαRII were assayed at four-time points (V0, baseline; V1, pre-surgery; V2, 1 hr post-surgery, and V3, 72 hrs post-surgery). Comorbidities and Hospital Anxiety and Depression (HADS) questionnaires were administrated before and at 6 hrs after the surgery. All patients were treated with cold patches, topical steroids, topical cold antibiotics, and benzodiazepines after ASA surgery. A descriptive analysis of biomarkers and pain intensity evolution and the agreement between biomarkers and pain was performed. Results: Concentration of sIgA and sTNFαRII post-surgery was significantly higher at each visit compared to baseline (p-value: 0.053, p-value: < 0.001, respectively). Relations between VAS scale score and putative biomarker variations were not statistically significant except for the sIgA but only at visit 0 (p-value: 0.024). The HADS questionnaire showed anxiety scores between 0 and 7 in all patients before and at 6 hrs after surgery. Conclusion: In this study, sIgA and sTNFαRII are the two potential biomarkers that present correlation with the VAS and these salivary substances showed acceptable levels of reproducibility in healthy subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Natural History of Anal Squamous Intraepithelial Lesions in HIV-Positive Men with Normal Baseline Cytology.
- Author
-
Revollo, Boris, Videla, Sebastián, Sirera, Guillem, García-Cuyás, Francesc, Parés, David, Corral, Javier, Clotet, Bonaventura, and Llibre, Josep M.
- Subjects
PAPILLOMAVIRUS diseases ,SEXUALLY transmitted disease risk factors ,ANTIRETROVIRAL agents ,CONFIDENCE intervals ,HIV-positive persons ,LONGITUDINAL method ,MEN'S health ,RISK assessment ,SQUAMOUS cell carcinoma ,DISEASE incidence ,HIV seroconversion ,MEN who have sex with men ,TUMOR grading ,ANAL intraepithelial neoplasia ,DISEASE risk factors - Abstract
The natural history of squamous intraepithelial lesions (SILs) in the anal canal of HIV-infected men is incompletely understood. We assessed the incidence and factors associated with SIL and invasive anal squamous cell carcinoma (IASCC) among HIV-infected men with normal cytology at baseline. We performed a single-center prospective cohort study [men who have sex with men (MSM) and men who have sex with women (MSW)]. The incidence of anal canal SIL (low grade and high grade) and IASCC were estimated and predictive factors analyzed. The study population comprised 297 HIV-infected men with a normal cytology result and no anal human papillomavirus (HPV)-related diseases. Of these, 251 (85%) had at least one evaluable set of cytology data during follow-up (172 MSM, 79 MSW). The median follow-up time was 4 years. The cumulative incidence of SIL was 43% (107/251): 52% in MSM (90/172) and 22% in MSW (17/79), p < 0.0001. The incidence rate of SILs was 109 (95% confidence interval = 90–132) per 1000 person-years: 142 in MSM and 49 in MSW, p < 0.0001. HPV infection, receiving antiretroviral treatment (ART), and being MSM were independently associated risk factors. The incidence of IASCC was 0.15 per 1000 person-years among MSM and 0 in MSW. HIV-infected men, both MSM and MSW, are at high risk of developing SIL despite having a normal anal cytology at baseline. The incidence of anal canal SIL was higher among MSM, but was also remarkable among MSW. Independent risk factors associated with SIL were being HIV-infected MSM at high risk for acquisition of STIs, time on ART, and HPV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up.
- Author
-
Videla, Sebastián, Tarrats, Antoni, Ornelas, Arelly, Badia, Roger, Castella, Eva, Alcalde, Carme, Chamorro, Anna, Esté, José A., Clotet, Bonaventura, and Sirera, Guillem
- Subjects
CERVICAL intraepithelial neoplasia ,CARCINOMA in situ ,SQUAMOUS cell carcinoma ,WOMEN ,INFECTION - Abstract
Currently, Papanicolaou smears are proposed at three-year intervals for cervical screening to all women living with HIV. The aim of this retrospective cohort study was to provide data on the incidence of cervical high-grade squamous intraepithelial lesions (HSIL) in cervical smear confirmed by histology in HIV-1-infected women (two consecutive normal Papanicolaou smears at baseline) after a long-term follow-up. Sixty-seven women (recruited between March 1999 and January 2003) were analyzed. The median period of follow-up was 13.2 years (range: 7.4-17.1 years) with a total of 583 Papanicolaou smears. Twenty-seven percent of these HIV-1-infected women had poorly-controlled HIV. Cumulative incidence of HSIL was 18% (12/67; 95%CI: 11-29%) of which one was an invasive squamous cell carcinoma and two were carcinoma in situ. These women had not been well-engaged with the annual Papanicolaou smear screening program and had poor adherence to antiretroviral therapy. Development of HSIL was associated with high-risk-HPV infection (OR: 14.9; 95%CI: 3.0, 75.1). At last Papanicolaou smear, prevalence of high-risk-HPV infection was 30% (20/66, 95%CI: 21-42%). In conclusion, the incidence of cervical HSIL in HIV-1-infected women with poor antiretroviral therapy adherence or poor immunological status reinforces the need to identify those HIV-1-infected women at risk of developing cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. The effect of APOE ɛ4 in Alzheimer's disease biomarkers in Down syndrome: Neuroimaging: Other neurodegenerative disorders.
- Author
-
Vilaplana, Eduard, Videla, Laura, Carmona‐Iragui, Maria, Benejam, Bessy, Barroeta, Isabel, Fernandez, Susana, Altuna, Miren, Pegueroles, Jordi, Montal, Victor, Bejanin, Alexandre, Iulita, M. Florencia, Valldeneu, Sílvia, González‐Ortiz, Sofía, Muñoz, Laia, Camacho, Valle, Videla, Sebastián, Alcolea, Daniel, Blesa, Rafael, Lleó, Alberto, and Clarimon, Jordi
- Published
- 2020
- Full Text
- View/download PDF
20. The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers.
- Author
-
Encina, Gregorio, Encabo, Mercedes, Escriche, Marisol, Lahjou, Mounia, Sicard, Eric, Smith, Kevin, Gascon, Neus, Plata-Salamán, Carlos, and Videla, Sebastián
- Subjects
TRAMADOL ,DRUG administration ,BIOAVAILABILITY ,DRUG dosage ,DRUG tablets ,THERAPEUTICS - Abstract
Background and Objective: Co-Crystal of Tramadol-Celecoxib (CTC), in development for the treatment of moderate to severe acute pain, is a first-in-class co-crystal containing a 1:1 molecular ratio of two active pharmaceutical ingredients; rac-tramadol·HCl and celecoxib. This randomised, open-label, crossover study compared the bioavailability of both components after CTC administration under fed and fasting conditions.Methods: Healthy adults received single doses of 200 mg CTC under both fed and fasting conditions (separated by a 7-day washout). Each dose of CTC was administered orally as two 100 mg tablets, each containing 44 mg tramadol·HCl and 56 mg celecoxib. In the fed condition, a high-fat, high-calorie meal [in line with recommendations by the US Food and Drug Administration (FDA)] was served 30 min before CTC administration. Tramadol, O-desmethyltramadol and celecoxib plasma concentrations were measured pre- and post-dose up to 48 h. Pharmacokinetic parameters were calculated using non-compartmental analysis. Safety was also assessed.Results: Thirty-six subjects (18 female/18 male) received one or both doses of CTC; 33 provided evaluable pharmacokinetic data under fed and fasting conditions. For tramadol and O-desmethyltramadol, fed-to-fasting ratios of geometric least-squares means and corresponding 90% confidence interval (CI) values for maximum plasma concentration (C
max ) and extrapolated area under the plasma concentration-time curve to infinity (AUC∞ ) were within the pre-defined range for comparative bioavailability (80-125%). For celecoxib, Cmax and AUC∞ fed-to-fasting ratios (90% CIs) were outside this range, at 130.91% (116.98-146.49) and 129.34% (121.78-137.38), respectively. The safety profile of CTC was similar in fed and fasting conditions.Conclusions: As reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose CTC. Food had no effect on tramadol or O-desmethyltramadol bioavailability.Clinical trial registration number: 152052 (registered with the Therapeutic Products Directorate of Health Canada) [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial.
- Author
-
López-Cedrún, José, Videla, Sebastián, Burgueño, Miguel, Juárez, Inma, Aboul-Hosn, Samir, Martín-Granizo, Rafael, Grau, Joan, Puche, Miguel, Gil-Diez, José-Luis, Hueto, José-Antonio, Vaqué, Anna, Sust, Mariano, Plata-Salamán, Carlos, Monner, Antoni, and On behalf of the Co-Crystal of Tramadol-Celecoxib Team
- Subjects
CELECOXIB ,TRAMADOL ,ORAL surgery ,ORAL diseases - Abstract
Background: Co-crystal of tramadol-celecoxib (CTC), containing equimolar quantities of the active pharmaceutical ingredients (APIs) tramadol and celecoxib (100 mg CTC = 44 mg rac-tramadol hydrochloride and 56 mg celecoxib), is a novel API-API co-crystal for the treatment of pain. We aimed to establish the effective dose of CTC for treating acute pain following oral surgery.Methods: A dose-finding, double-blind, randomised, placebo- and active-controlled, multicentre (nine Spanish hospitals), phase II study (EudraCT number: 2011-002778-21) was performed in male and female patients aged ≥ 18 years experiencing moderate to severe pain following extraction of two or more impacted third molars requiring bone removal. Eligible patients were randomised via a computer-generated list to receive one of six single-dose treatments (CTC 50, 100, 150, 200 mg; tramadol 100 mg; and placebo). The primary efficacy endpoint was the sum of pain intensity difference (SPID) over 8 h assessed in the per-protocol population.Results: Between 10 February 2012 and 13 February 2013, 334 patients were randomised and received study treatment: 50 mg (n = 55), 100 mg (n = 53), 150 mg (n = 57), or 200 mg (n = 57) of CTC, 100 mg tramadol (n = 58), or placebo (n = 54). CTC 100, 150, and 200 mg showed significantly higher efficacy compared with placebo and/or tramadol in all measures: SPID (0-8 h) (mean [standard deviation]): − 90 (234), − 139 (227), − 173 (224), 71 (213), and 22 (228), respectively. The proportion of patients experiencing treatment-emergent adverse events was lower in the 50 (12.7% [n = 7]), 100 (11.3% [n = 6]), and 150 (15.8% [n = 9]) mg CTC groups, and similar in the 200 mg (29.8% [n = 17]) CTC group, compared with the tramadol group (29.3% [n = 17]), with nausea, dizziness, and vomiting the most frequent events.Conclusion: Significant improvement in the benefit-risk ratio was observed for CTC (doses ≥ 100 mg) over tramadol and placebo in the treatment of acute pain following oral surgery.Funding: Laboratorios del Dr. Esteve, S.A.U. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial.
- Author
-
Videla, Sebastián, Lahjou, Mounia, Vaqué, Anna, Sust, Mariano, Escriche, Marisol, Soler, Lluis, Sans, Artur, Sicard, Eric, Gascón, Neus, Encina, Gregorio, and Plata‐Salamán, Carlos
- Subjects
PHARMACOKINETICS ,CELECOXIB ,TRAMADOL ,DRUG dosage ,DRUG side effects ,MEDICATION safety ,CLINICAL trials - Abstract
Aim We compared the pharmacokinetic (PK) profiles of co-crystal of tramadol-celecoxib (CTC) vs. each reference product (alone and in open combination) after single (first dose) and multiple dosing. Methods Healthy adults aged 18-50 years received, under fasted conditions, 15 twice-daily doses of the following treatments (separated by ≥14-day washout): 200 mg immediate-release (IR) CTC (equivalent to 88 mg tramadol and 112 mg celecoxib; treatment 1); 100 mg IR tramadol (treatment 2), 100 mg celecoxib (treatment 3); and 100 mg IR tramadol and 100 mg celecoxib (treatment 4). The treatment sequence was assigned by computer-generated randomization. PK parameters were calculated using non-compartmental analysis. Parameters for CTC were adjusted according to reference product dose. Results A total of 30 subjects (20 males, mean age 35 years) were included. Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml
−1 [mean maximum plasma concentration ( Cmax )]; 4796, 4990 and 5284 ng h ml−1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state). For treatments 1, 3 and 4, multiple-dose celecoxib PK parameters were 445, 536 and 396 ng ml−1 ; 2803, 3366 and 2897 ng h ml−1 ; and 2.0, 2.0 and 3.0 h. Single-dose findings were consistent with multiple-dose data. Types of adverse events were consistent with known reference product safety profiles. Conclusion After single (first dose) and multiple dosing, PK parameters for each active pharmaceutical ingredient in CTC were modified by co-crystallization compared with reference products alone or in open combination. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
- Author
-
Bruna, Jordi, Videla, Sebastián, Argyriou, Andreas A., Velasco, Roser, Villoria, Jesús, Santos, Cristina, Nadal, Cristina, Cavaletti, Guido, Alberti, Paola, Briani, Chiara, Kalofonos, Haralabos P., Cortinovis, Diego, Sust, Mariano, Vaqué, Anna, Klein, Thomas, and Plata-Salamán, Carlos
- Abstract
This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn). A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial. Outcome measures included changes in 24-week quantitative measures of thermal sensitivity and total neuropathy score. In total, 124 patients were randomized (1:1) to MR309 or placebo. Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles. Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054). MR309 significantly reduced cold pain threshold temperature [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032]. Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminology Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046). The total amount of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049). Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, respectively). Intermittent treatment with MR309 was associated with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn. Furthermore, MR309 showed an acceptable safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects.
- Author
-
Videla, Sebastián, Lahjou, Mounia, Vaqué, Anna, Sust, Mariano, Encabo, Mercedes, Soler, Lluis, Sans, Artur, Sicard, Eric, Gascón, Neus, Encina, Gregorio, and Plata‐Salamán, Carlos
- Subjects
PHARMACOKINETICS ,TRAMADOL ,CELECOXIB ,CLINICAL drug trials ,PAIN management - Abstract
Aims Co-crystal of tramadol-celecoxib (CTC) is a novel co-crystal molecule containing two active pharmaceutical ingredients under development by Esteve (E-58425) and Mundipharma Research (MR308). This Phase I study compared single-dose pharmacokinetics (PK) of CTC with those of the individual reference products [immediate-release (IR) tramadol and celecoxib] alone and in open combination. Methods Healthy adults aged 18-55 years were orally administered four treatments under fasted conditions (separated by 7-day wash-out period): 200 mg IR CTC (equivalent to 88 mg tramadol and 112 mg celecoxib; Treatment 1); 100 mg IR tramadol (Treatment 2); 100 mg celecoxib (Treatment 3); and 100 mg IR tramadol and 100 mg celecoxib (Treatment 4). Treatment sequence was assigned using computer-generated randomization. PK parameters were calculated using noncompartmental analysis with parameters for CTC adjusted according to reference product dose (100 mg). Results Thirty-six subjects (28 male, mean age 36 years) participated. Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml
-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration). For Treatments 1, 3 and 4, the respective celecoxib PK parameters were 313, 449 and 284 ng ml-1 ; 2183, 3093 and 2856 ng h ml-1 ; and 1.5, 2.3 and 3.0 h. No unexpected adverse events were reported. Conclusion PK parameters of each API in CTC were modified by co-crystallization compared with marketed formulations of tramadol, celecoxib, and their open combination. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
25. Home monitoring vs hospitalization for mild acute pancreatitis. A pilot randomized controlled clinical trials.
- Author
-
Sorribas, Maria, Carnaval, Thiago, Peláez, Núria, Secanella, Luis, Salord, Silvia, Sarret, Sònia, Videla, Sebastián, and Busquets, Juli
- Published
- 2023
- Full Text
- View/download PDF
26. Pain perception description after advanced surface ablation.
- Author
-
Sobas, Eva M., Videla, Sebastián, Vázquez, Amanda, Fernández, Itziar, Maldonado, Miguel J., and Pastor, José-Carlos
- Subjects
POSTOPERATIVE pain treatment ,CATHETER ablation ,PAIN perception ,MENTAL depression ,VISUAL analog scale - Abstract
Purpose: The objective of this study was to characterize the evolution of ocular pain after advanced surface ablation (ASA) to improve strategies in postoperative pain management. Methods: This was a multicenter, prospective, descriptive, cohort study. The inclusion criteria were healthy individuals ≥18 years old receiving bilateral alcohol-assisted surface ablation with epithelial removal. Pain intensity was evaluated with the visual analog scale (VAS) and the numeric pain rating scale before and after surgery. Comorbidities (photophobia, burning, tearing, and foreign body sensation) and Hospital Anxiety and Depression (HAD) questionnaire were evaluated before and at 6 hours after surgery. Postoperative treatments included cold patch, topical cold antibiotics, topical steroids, and benzodiazepines. Results: Thirty-two consecutive patients having similar profiles of postoperative pain evolution were included. At 0.5 hour after ASA, the pain score by VAS was 37±20 mm, and the maximum pain, 61±31 mm, occurred at 24 hours. Afterward, it decreased progressively until 72 hours after surgery (19±20 mm). Most patients (81%) scored .60 mm, and 44% required rescue medication. Among the comorbidities, all patients had photophobia and 84% had burning sensation. At 6 hours, the HAD score was 5.4±3.9, within the range of values considered as normal. Conclusion: Postoperative acute ocular pain after ASA showed a characteristic evolution over time. Recognition of the pattern could be important for improving the acceptance of ASA and for improving strategies in pain management in the postoperative period. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.
- Author
-
Carmona-Iragui, María, Fortea, Juan, Alcolea, Daniel, Blesa, Rafael, Lleó, Alberto, Fernández, Susana, Benejam, Bessy, Videla, Laura, Videla, Sebastián, Santos, Telma, and Blennow, Kaj
- Subjects
ALZHEIMER'S disease ,LUMBAR puncture ,CEREBROSPINAL fluid ,DOWN syndrome ,DISEASE complications ,PILOT projects ,RETROSPECTIVE studies - Abstract
Background: Alzheimer's disease (AD) is the main medical problem in older adults with Down syndrome (DS). Studies of cerebrospinal fluid (CSF) AD biomarkers are limited and the feasibility of lumbar puncture (LP) is controversial in this population.Objective: To analyze the frequency of complications after a LP in DS.Methods: We collected data from 80 adults with DS that underwent a LP within the Down Alzheimer Barcelona Neuroimaging Initiative. Demographics, cognitive status, headache history, and presence of complications after the LP were recorded in every subject. In 53 of them (active group), this information was collected following a semi-structured and validated protocol that actively looks for complications. Other variables related to the LP procedure were also recorded. A telephone interview to the caregiver was performed 5-7 days after the procedure to ask about complications. Data from 27 subjects (clinical practice group), from whom the presence of complications was obtained in a medical follow-up visit within the three months after the LP, were also included.Results: There were no adverse events in 90% of our participants. The most frequent complication was headache (6.25%); only one subject reported a typical post-lumbar puncture headache with moderate severity that required analgesic treatment. Dizziness (3.75%) and back pain (1.25%) were also reported. All the participants that reported complications belonged to the active group.Conclusion: LP can be safely performed to study CSF biomarkers in DS. The reported complications are qualitatively similar to the general population, but are less frequently reported, even when actively searched for. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. O2‐09‐01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME.
- Author
-
Fortea, Juan, Vilaplana, Eduard, Carmona-Iragui, Maria, Benejam, Bessy, Fernandez, Susana, Videla, Laura, Barroeta, Isabel, Altuna, Miren, Alcolea, Daniel, Pegueroles, Jordi, Montal, Victor, Muñoz-Llahuna, Laia, Estellés, Teresa, Illán-Gala, Ignacio, González-Ortiz, Sofía, Camacho, Valle, Lehmann, Sylvain, Clarimon, Jordi, Videla, Sebastián, and Blesa, Rafael
- Published
- 2019
- Full Text
- View/download PDF
29. Groin surgical site infection incidence in vascular surgery with intradermal suture versus metallic stapling skin closure: A study protocol for a pragmatic open-label parallel-group randomized clinical trial (VASC-INF trial).
- Author
-
González-Sagredo, Albert, Gil, Miquel, D'Oria, Mario, Spanos, Konstantinos, Salinas, Álvaro, Matus, Selene, Carnaval, Thiago, Llagostera, Secundino, Lepidi, Sandro, Giannoukas, Athanasios, Bellmunt, Sergi, García-Vidal, Raul, Videla, Sebastián, Vila, Ramon, and Iborra, Elena
- Published
- 2022
- Full Text
- View/download PDF
30. Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study.
- Author
-
Secanella, Luis, Busquets, Juli, Peláez, Núria, Sorribas, María, Laquente, Berta, Ruiz, Sandra, Carnaval, Thiago, Videla, Sebastián, and Fabregat, Juan
- Published
- 2022
- Full Text
- View/download PDF
31. Suspected adverse events following immunization against SARS-CoV2 in a university hospital in 2021: Observational study.
- Author
-
Rodríguez, Dolores, Ordoñez, Pilar, Llop, Roser, Videla, Sebastián, Otero, Aurema, Carnaval, Thiago, Poltorak, Violeta, Moya-Guerola, Miguel, Masuet-Aumatell, Cristina, Rodriguez, Soledad, and Hereu, Pilar
- Published
- 2022
- Full Text
- View/download PDF
32. Ocular pain and discomfort after advanced surface ablation: an ignored complaint.
- Author
-
Sobas, Eva M., Videla, Sebastián, Maldonado, Miguel J., and Pastor, Jose C.
- Subjects
LASERS in ophthalmology ,OPHTHALMIC surgery ,TREATMENT of eye refractive errors ,TREATMENT of eye diseases ,ABLATION techniques - Abstract
Purpose: Laser vision correction is one of the most commonly performed elective surgical procedures in ophthalmology. Generally, discomfort besides pain (photophobia, burning sensation, tearing, and foreign body sensation) after these procedures is not taken into consideration in the clinical practice. The objective is to provide data on these symptoms and their relevance after advanced surface ablation (ASA). Methods: Single-center survey study based on a structured questionnaire relative to the patients' perceived symptoms after ASA. Inclusion criteria were: ≥18 years old, no ocular disease, with myopia (0.75 to 9 D) or hyperopia (0.25 to 5 D) with or without astigmatism, receiving ASA on at least one eye. All procedures were performed by the same surgeon. A descriptive analysis was performed. Results: Seventy-three consecutive patients (34 men and 39 women) were included in the study. The median (range) of age was 33 (19-64) years. Sixty-nine patients had surgery done on both eyes. Postoperative pain was the most frequent comorbidity (97% [95% confidence interval {CI}: 90-100]) with a median (range) of intensity (verbal numerical rating scale) score of 7 (2-10). Photophobia: 85% (95% CI: 75-92); burning sensation: 62% (95% CI: 50-73); tearing: 59% (95% CI: 47-70); and foreign body sensation: 48% (95% CI: 36-60) were also prevalent postoperative symptoms. Pain during ASA was reported for 44% (95% CI: 32-56) of patients. Conclusion: Comorbidities such as pain, photophobia, burning sensation, tearing, and foreign body sensation are prevalent after ASA procedure. Postoperative pain should be taken into consideration due to its prevalence and intensity. A new and more efficient postoperative analgesic protocol should be established. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages.
- Author
-
Videla, Sebastián, Darwich, Laila, Cañadas, MariPaz, Clotet, Bonaventura, and Sirera, Guillem
- Published
- 2014
- Full Text
- View/download PDF
34. 1H‐MRS signature in Alzheimer disease in Down syndrome: Neuroimaging / Optimal neuroimaging measures for tracking disease progression.
- Author
-
Barroeta, Isabel, Montal, Victor, Carmona‐Iragui, Maria, Pegueroles, Jordi, Vilaplana, Eduard, Bejanin, Alexandre, González‐Ortiz, Sofía, Altuna, Miren, Benejam, Bessy, Alcolea, Daniel, Videla, Laura, Valldeneu, Sílvia, Fernandez, Susana, Videla, Sebastián, Blesa, Rafael, Clarimon, Jordi, Lleó, Alberto, and Fortea, Juan
- Published
- 2020
- Full Text
- View/download PDF
35. Pharmacokinetic Dose Proportionality Between Two Strengths (12.5 mg and 25 mg) of Doxylamine Hydrogen Succinate Film-Coated Tablets in Fasting State: A Single-Dose, Randomized, Two-Period Crossover Study in Healthy Volunteers.
- Author
-
Videla, Sebastián, Cebrecos, Jesús, Lahjou, Mounia, Wagner, France, Guibord, Pascal, Xu, Zhengguo, Cabot, Anna, Encabo, Mercedes, Encina, Gregorio, Sicard, Eric, and Sans, Artur
- Subjects
PHARMACOKINETICS ,SUCCINATES ,ORAL medication ,RANDOMIZED controlled trials ,HIGH performance liquid chromatography - Abstract
Background: Doxylamine succinate, an ethanolamine-based antihistamine, is used in the short-term management of insomnia because of its sedative effects. No data on the dose proportionality of the pharmacokinetics of doxylamine are available, although this drug has been marketed in European countries for more than 50 years. Objective: The objective of this study was to evaluate and compare the dose proportionality between two marketed strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate after a single oral dose administration under fasting conditions in healthy human subjects. Study Design: This was a single-center, randomized, single dose, laboratory-blinded, two-period, two-sequence, crossover study. Setting: The study was conducted in a phase I clinical unit. Subjects and Methods: A single oral dose of doxylamine hydrogen succinate of 12.5 mg (equivalent to 8.7 mg of doxylamine base) or 25 mg (equivalent to 17.4 mg of doxylamine base) was administered to healthy volunteers under fasting conditions in each study period. The drug administrations were separated by a wash-out period of 7 calendar days. Blood samples were collected for up to 60 h post-dose, and plasma doxylamine levels were determined by an ultra high-performance liquid chromatography method with tandem mass spectrometry detection. Pharmacokinetic parameters were calculated using non-compartmental analysis. Dose proportionality was assessed based on the parameter area under the concentration-time curve (AUC). Safety was evaluated through assessment of adverse events, standard laboratory evaluations, vital signs and 12-lead electrocardiogram (ECG). Results: In total, 12 healthy volunteers (3 male; 9 female) were included in the study. Mean maximum observed plasma concentration ( C) and area under the concentration-time curve from time zero to time t (AUC) of doxylamine hydrogen succinate 12.5 mg and 25 mg tablets increased linearly and dose-dependently [12.5 mg: mean C 61.94 ng/mL, coefficient of variation (CV) 23.2 %; mean AUC 817.33 ng·h/mL, CV 27.4 %; and 25 mg: mean C 124.91 ng/mL, CV 18.7 %; mean AUC 1630.85 ng·h/mL, CV 22.8 %]. Mean AUC was 815.43 ng·h/mL, CV 22.8 % for 25 mg. The dose-normalized geometric mean ratio (%, 12.5 mg/25 mg) of AUC was 98.92 (90 % CI: 92.46, 105.83). The most common adverse event was somnolence. Conclusions: Exposure to doxylamine was proportional over the therapeutic dose range of 12.5-25 mg in healthy volunteers. Based on the results, a predictable and linear increase in systemic exposure can be expected. Doxylamine hydrogen succinate was safe and well tolerated. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women.
- Author
-
Sirera, Guillem, Videla, Sebastián, Piñol, Marta, Coll, Josep, García-Cuyás, Francesc, Vela, Sandra, Cañadas, Maripaz, Darwich, Laila, Pérez, Núria, Gel, Silvia, Cobarsi, Patricia, Clotet, Bonaventura, and HIV-HPV Study Group
- Published
- 2013
- Full Text
- View/download PDF
37. Food Effects on the Pharmacokinetics of Doxylamine Hydrogen Succinate 25 mg Film-Coated Tablets.
- Author
-
Videla, Sebastián, Lahjou, Mounia, Guibord, Pascal, Xu, Zhengguo, Tolrà, Carles, Encina, Gregorio, Sicard, Eric, and Sans, Artur
- Subjects
ANTIHISTAMINES ,PHARMACOKINETICS ,CLINICAL trials ,SEDATIVES ,FOOD consumption ,BIOAVAILABILITY - Abstract
Background: Doxylamine succinate, an ethanolamine-based antihistamine, is used in the short-term management of insomnia because of its sedative effects. The data available on the pharmacokinetic profile of doxylamine in humans are limited, notwithstanding that this drug has been marketed in European countries for more than 50 years. In fact, no data on the effect of food on the pharmacokinetic parameters of doxylamine are available. Objective: The objective of this study was to evaluate the pharmacokinetic parameters of doxylamine following a single oral dose of doxylamine hydrogen succinate 25 mg in healthy human subjects under fed and fasting conditions. Study Design: This was a single-center, randomized, single-dose, laboratory-blinded, two-period, two-sequence, crossover study. Setting: The study was conducted in a phase I clinical unit. Subjects and Methods: A single oral dose of doxylamine hydrogen succinate 25 mg (equivalent to 17.4 mg of doxylamine base) was administered to healthy volunteers under either fed conditions (high-fat, high-calorie food intake) or fasting conditions in each study period. The drug administrations were separated by a wash-out period of seven calendar days. Plasma samples were collected for up to 60 hours postdose, and plasma doxylamine concentrations were determined by a high-performance liquid chromatography method with tandem mass spectrometry detection. Pharmacokinetic parameters were calculated using noncompartmental analysis. Safety was evaluated through assessment of adverse events, standard laboratory evaluations, vital signs, and 12-lead electrocardiography. Results: In total, 24 healthy subjects (12 male and 12 female) were included in the study. Doxylamine succinate 25 mg tablets exhibited similar oral bioavailability of doxylamine in the fasting state (mean maximum plasma drug concentration [C] 118.21 ng/mL, coefficient of variation [CV] 19.2%; mean area under the plasma concentration time curve from time zero to time t [AUC] 1746.97 ng · h/mL, CV 31.6%) and in the fed state (mean C 120.99 ng/mL, CV 15.0%; mean AUC 1712.20 ng · h/mL, CV 26.7%). No statistically significant between-treatment differences were observed for any of the pharmacokinetic parameters under study. The fed: fasting ratios of the geometric least squares means with corresponding 90% confidence intervals for C and AUC were within the range of 80-125%. Conclusion: High-fat, high-calorie food intake does not affect the kinetics of doxylamine in healthy subjects. The drug was safe and well tolerated by the subjects in this study. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
38. SPECT-CT metabolic and morphological study of 2 types of cemented hip stem prostheses in primary total hip arthroplasty patients: A protocol for a randomized controlled clinical trial (SPECT-PROTMA).
- Author
-
Rodríguez, Daniel, Carnaval, Thiago, del Carmen, Marcos, Palomar-Muñoz, Azahara, Cortés-Romera, Montserrat, Agulló, José-Luis, and Videla, Sebastián
- Published
- 2021
- Full Text
- View/download PDF
39. Calcium Dobesilate for the Treatment of Erectile Dysfunction in Men with Diabetes Mellitus.
- Author
-
Videla, Sebastián, Villoria, Jesús, Sust, Mariano, Drábek, František, Všetička, Jaroslav, Pavlik, Ivan, Kawaciuk, Ivan, Louda, Miroslav, García, Carmen, Angulo, Javier, and Sáenz de Tejada, Ínigo
- Subjects
DIABETES ,PEOPLE with diabetes ,IMPOTENCE ,CLINICAL trials ,PATIENTS ,MEDICAL experimentation on humans - Abstract
Calcium dobesilate has shown to improve endothelial function. This proof-of-concept clinical trial was done to check whether it may improve erectile dysfunction in diabetic men. Male diabetic patients with a diagnosis of erectile dysfunction were randomized to receive either calcium dobesilate 1 g twice per day or placebo for 6 weeks. The International Index of Erectile Function (IIEF) was chosen as the primary efficacy measurement. Statistical procedures included a pre-scheduled adaptive interim analysis to recalculate sample size. Relevant, but not significant differences in the mean change from baseline in the primary end-point (IIEF questions 3, 4 and 7) favouring dobesilate with respect to placebo were observed. Such differences reached statistical significance in some secondary end-points, including IIEF global as well as the erectile function and intercourse satisfaction domains’ scores. Some patients experienced an important placebo effect. Results suggest that dobesilate may be of help to treat diabetic erectile dysfunction. Co-administration with phosphodiesterase inhibitors warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
40. Polyethylene glycol enhances colonic barrier function and ameliorates experimental colitis in rats.
- Author
-
Videla, Sebastián, Lugea, Aurelia, Vilaseca, Jaime, Guarner, Francisco, Treserra, Francesc, Salas, Antonio, Crespo, Ernesto, Medina, Carlos, and Malagelada, Juan
- Subjects
POLYETHYLENE glycol ,PATHOGENIC microorganisms ,COLITIS ,DRINKING water ,COLON diseases - Abstract
Polyethylene glycol (PEG) has been suggested to protect against pathogen colonization by improving colonic barrier function. We aimed to establish whether PEG 4000 affects colonic barrier function and the development of colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in rats. PEG was included in the drinking water for a period of 48 h before intracolonic administration of TNBS. PEG increased colonic surface hydrophobicity and diminished luminal bacterial load. Moreover, PEG markedly reduced mucosal damage and inflammation induced by TNBS. This protection effect appeared to be independent of its laxative properties since the laxatives mannitol or senna extracts had no effect on TNBS colitis. Using everted colonic sacs, pretreatment with PEG produced a lasting reduction in epithelial permeability to mannitol and dextran-70 K that correlated with decreased surface hydrophobicity. Our results suggest that the protective effect of PEG on TNBS colitis is associated with reinforcement of the epithelial barrier. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
41. Long-Term Efficacy of Octreotide in the Prevention of Recurrent Bleeding from Gastrointestinal Angiodysplasia.
- Author
-
Junquera, Félix, Saperas, Esteban, Videla, Sebastián, Feu, Faust, Vilaseca, Jaime, Armengol, José Ramón, Bordas, Josep María, Piqu, Josep María, and Malagelada, Juan-Ramón
- Subjects
DRUG efficacy ,ANTINEOPLASTIC agents ,BLOOD-vessel abnormalities ,HEMORRHAGE ,THERAPEUTICS ,CLINICAL trials - Abstract
OBJECTIVES: Preliminary studies suggested that octreotide may be therapeutic in bleeding angiodysplasia. Our aim was to investigate the efficacy of long-term octreotide therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. METHODS: A cohort of 32 patients diagnosed with bleeding from angiodysplasia was treated with octreotide 50 μ 12 h subcutaneously for a 1–2 yr period. This cohort was compared with an external control group (38 patients who had received placebo [1 tablet/day] in a concurrent randomized clinical trial for the same period. RESULTS: Two patients of the octreotide group were lost to follow-up. Treatment failure occurred in seven of 30 (23%) patients in the octreotide group and in 17 of 35 (48%) in the placebo group (three dropouts before first visit) ( P= 0.043). The actuarial probability of remaining free of rebleeding at 1 and 2 yr of follow-up was 77% and 68%, respectively, for the octreotide group and 55% and 36%, respectively, for the placebo group (log rank P= 0.030). Multivariate proportional hazards-regression analysis showed that octreotide therapy and previous bleeding episodes were positive and negative predictors of efficacy, respectively. No significant differences between the groups were observed according to number of bleeding episodes (0.4 ± 0.7 vs 0.9 ± 1.5, P= 0.070) and transfusion requirements (1.1 ± 2.6 vs 0.7 ± 1.5 units); however, iron requirements were lower in the octreotide than in the placebo group (22 ± 62 vs 166 ± 267 units; P < 0.001). Likewise, major adverse events (1 vs 1) and mortality (0 vs 1) were similar between groups. CONCLUSIONS: This study suggests that octreotide treatment may be beneficial in preventing rebleeding from gastrointestinal angiodysplasia. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
42. Outcome of Patients With Ischemic Colitis: Review of Fifty-Three Cases.
- Author
-
Medina, Carlos, Vilaseca, Jaime, Videla, Sebastián, xF3;n#Fabra, Ram&, Armengol-Miro, J. R., and Malagelada, J.-R.
- Subjects
ISCHEMIC colitis ,INTESTINAL ischemia ,PATIENTS ,DISEASE risk factors ,WOMEN patients ,DIAGNOSIS - Abstract
PURPOSE: Ischemic colitis is a disease of elderly patients and includes a wide clinical spectrum ranging from mild to severe forms. Some patients may develop complications. Management of this disorder depends on disease severity. Our aim was to review the clinical characteristics of patients diagnosed of ischemic colitis and analyze predictive factors of poor prognosis. METHODS: This study is a retrospective analysis of 53 cases of ischemic colitis (33 men, 20 women), 35 with moderate and 18 with severe forms, respectively. Clinical characteristics, diagnostic procedures, segment of colon involved and long-term evolution after discharge were analyzed. RESULTS: Hypertension (51 percent) was the main risk factor associated with ischemic colitis. Clinical presentation did not differ between groups, except for peritonitis which was present only in the severe group. Colonoscopy and histologic studies were the most used diagnostic procedures (90 percent). Peripheral vasculopathy (P < 0.01) and right colonic involvement (P < 0.001) were risk factors for severe outcome. Five patients died during admission. Among these, the right colon was affected in four (80 percent). No patient in either group developed chronic ischemic colitis during follow-up. CONCLUSION: Ischemic colitis usually runs a benign course after acute colonic insult. Peripheral vasculopathy and right colonic involvement are associated with severe forms of ischemic colitis. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
43. Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries.
- Author
-
Angulo, Javier, Cuevas, Pedro, Fernandez, Argentina, Gabancho, Sonia, Videla, Sebastián, and de Tejada, Iñigo Sáenz
- Subjects
IMPOTENCE ,TREATMENT of sexual dysfunction ,ENDOTHELIUM ,NITRIC-oxide synthases ,CYCLOOXYGENASES ,ACETYLCHOLINE - Abstract
1 We have evaluated the participation of endothelium-derived hyperpolarizing factor (EDHF) in the endothelium-dependent relaxation of isolated human penile resistance arteries (HPRA) and human corpus cavernosum (HCC) strips. In addition, the effect of the angioprotective agent, calcium dobesilate (DOBE), on the endothelium-dependent relaxation of these tissues was investigated. 2 Combined inhibition of nitric oxide synthase (NOS) and cyclooxygenase (COX) nearly abolished the endothelium-dependent relaxation to acetylcholine (ACh) in HCC. while 60% relaxation of HPRA was observed under these conditions. Endothelium-dependent relaxation of HPRA resistant to NOS and COX inhibition was prevented by raising the extracellular concentration of K
+ (35 mM) or by blocking Ca2 + -activated K+ channels, with apamin (APA: 100nM) and charybdotoxin (CTX: 100nM), suggesting the involvement of EDHF in these responses. 3 Endothelium-dependent relaxation to ACh was markedly enhanced by DOBE (10μM) in HPRA but not in HCC. The potentiating effects of DOBE on ACh-induced responses in HPRA, remained after NOS and COX inhibition, were reduced by inhibition of cytochrome P450 oxygenase with miconazole (0.3 mM) and were abolished by high K+ or a combination of APA and CTX. 4 In vivo, DOBE (l0mgkg-1 i.v.) significantly potentiated the erectile responses to cavernosal nerve stimulation in male rats. 5 EDHF plays an important role in the endothelium-dependent relaxation of HPRA but not in HCC. DOBE significantly improves endothelium-dependent relaxation of HPRA mediated by EDHF and potentiates erectile responses in vivo. Thus, EDHF becomes a new therapeutic target for the treatment of erectile dysfunction (ED) and DOBE could be considered a candidate for oral therapy for ED. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
44. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis.
- Author
-
Medina, Carlos, Videla, Sebastián, Radomski, Anna, Radomski, Marek W., Antolin, María, Guarner, Francisco, Vilaseca, Jaime, Salas, Antonio, and Malagelada, Juan-R.
- Subjects
METALLOPROTEINASES ,COLITIS ,INFLAMMATORY bowel diseases - Abstract
Matrix metalloproteinases may play a role in tissue remodelling and destruction associated with inflammation. We investigated activity and expression of matrix metalloproteinases in a rat model of colitis and tested the therapeutic potential of a synthetic inhibitor (CGS-27023-A). Colitis was induced by dextran sulphate sodium (at 5% in drinking water for 5 days) in a group of eight rats, whereas a matched control group received plain water. Activity and expression of matrix metalloproteinases were measured in colonic tissue homogenates using zymography and Western blot on days 3 and 5 after induction of colitis. In another set of experiments, two groups of colitic rats (20 per group) were treated with CGS-27023-A (20 mg/kg) or vehicle, respectively. On days 5 and 14, colonic mucosal lesions were blindly scored by microscopic examination. Induction of colitis led to a significant upregulation of matrix metalloproteinase-9 protein and its activity, but no change in matrix metalloproteinase-2 activity was observed. Treatment with CGS-27023-A significantly decreased the extent and severity of epithelial injury but did not influence mucosal repair. We conclude that increased activity of matrix metalloproteinases may contribute to epithelial damage in this model of colitis. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
45. Dietary Inulin Improves Distal Colitis Induced by Dextran Sodium Sulfate in the Rat.
- Author
-
Videla, Sebastián, Vilaseca, Jaime, Antolín, María, García-Lafuente, Ana, Guarner, Francisco, Crespo, Ernesto, Casalots, Jaume, Salas, Antonio, and Malagelada, Juan R.
- Subjects
INULIN ,COLITIS ,DEXTRAN ,SODIUM sulfate ,LACTIC acid bacteria ,LABORATORY rats - Abstract
OBJECTIVES: Inulin stimulates intracolonic generation of butyrate and growth of lactic acid bacteria. This study investigated whether inulin protects against colitis. METHODS: Rats with dextran sodium sulfate colitis received inulin either orally (1% in drinking water, or 400 mg/day) or by enema. Matched groups received vehicle. In addition, fecal water obtained from inulin-fed rats was administered by enema to rats with colitis and compared with fecal water from control rats. Finally, rats with colitis received daily enemas of either butyrate (at 40 or 80 mmol/L) or vehicle. Inflammation was assessed by eicosanoid asssay in rectal dialysates and MPO activity in colonic tissue. Mucosal lesions were blindly scored by microscopic examination. Luminal pH was measured from cecum to rectum by a surface microelectrode. RESULTS: Oral inulin prevented inflammation, as evidenced by lower lesion scores (p < 0.05). decreased release of mediators (p < 0.05), and lower tissue MPO (p < 0.05) as compared with controls. Inulin Induced acidic environment (pH < 7.0) from cecum to left colon and increased counts of lactobacilli. Fecal water from inulin-fed rats also reduced scores (p < 0.05) and inflammation (p < 0.05). However, inulin or butyrate enemas had no effect. CONCLUSIONS: Oral inulin reduces the severity of dextran sodium sulfate colitis. The effect seems to he mediated by modification of the intracolonic milieu. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
46. Prevalence of SARS-CoV-2 Infection at the University of Barcelona during the Third COVID-19 Pandemic Wave in Spain.
- Author
-
Videla, Sebastián, Otero, Aurema, Martí, Sara, Domínguez, M. Ángeles, Fabrellas, Nuria, Delgado-Hito, M. Pilar, Cruz, Imma, Tebé, Cristian, Vinuesa, Teresa, Ardila, Fernando, Sancho, Marta, Fernández, Esteve, Figuerola, Montserrat, and Ciruela, Francisco
- Published
- 2021
- Full Text
- View/download PDF
47. Stimulation of mucosal inflammatory activity by the normal fecal flora in a rat model of colitis.
- Author
-
Videla, Sebastián, Vilaseca, Jaime, Guarner, Francisco, Salas, Antonio, González, G., Antolín, Maria, and Malagelada, Juan-R.
- Published
- 1997
- Full Text
- View/download PDF
48. Impact of surgical technique and analgesia on clinical outcomes after lung transplantation: A STROBE-compliant cohort study.
- Author
-
Giménez-Milà, Marc, Videla, Sebastián, Pallarés, Natalia, Sabaté, Antoni, Parmar, Jasvir, Catarino, Pedro, Tosh, Will, Rafiq, Muhammad Umar, Nalpon, Jacinta, Valchanov, Kamen, and Chu., Danny
- Published
- 2020
- Full Text
- View/download PDF
49. P4‐076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME.
- Author
-
Carmona-Iragui, Maria, Videla, Laura, Benejam, Bessy, Alcolea, Daniel, Fernandez, Susana, Muñoz-Llahuna, Laia, Barroeta, Isabel, Videla, Sebastián, Blesa, Rafael, Lleó, Alberto, and Fortea, Juan
- Published
- 2018
- Full Text
- View/download PDF
50. STRUCTURAL CORRELATES OF ALZHEIMER’S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY.
- Author
-
Montal, Victor, Vilaplana, Eduard, Carmona-Iragui, Maria, Pegueroles, Jordi, González-Ortiz, Sofía, Benejam, Bessy, Alcolea, Daniel, Videla, Laura, Fernandez, Susana, Videla, Sebastián, Blesa, Rafael, Lleó, Alberto, and Fortea, Juan
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.